Literature DB >> 30645670

Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Christopher Pool1, Vonn Walter2,3,4, Darrin Bann1, David Goldenberg1, James Broach3,4, Max Hennessy1, Elizabeth Cottrill1, Erik Washburn5, Nicole Williams5, Henry Crist5, Yuka Imamura4, Joshua I Warrick6.   

Abstract

"Follicular variant" papillary thyroid carcinomas (FV-PTC) that do not histologically invade have a miniscule risk of metastasis, and thus been reclassified as a tumor of low malignant potential, the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). There are few molecular studies of this tumor type. We performed gene expression analysis, by RNA sequencing, on a series of FV-PTCs, NIFTPs, and follicular adenomas. A training set comprised tumors from The Cancer Genome Atlas (TCGA) repository (n = 46), digital slides from which were reviewed and classified as invasive or non-invasive FV-PTC. A validation set comprised in-house NIFTPs, invasive FV-PTCs, and follicular adenomas (n = 26). In the training set, unsupervised clustering separated tumors into three distinct expression subtypes, which associated with invasion and characteristic molecular alterations. Specifically, the "BRAF-like" subtype was enriched in invasive FV-PTCs and tumors with BRAF V600E mutations. The "THADA-like" subtype was enriched in non-invasive tumors and those with rearrangements involving THADA. The "RAS-family-like" subtype included many invasive and non-invasive FV-PTCs and was enriched in tumors with mutations in RAS family genes. In the validation set, nearest centroid analysis classified all invasive FV-PTCs as "BRAF-like" and all follicular adenomas as either "RAS-like" or "THADA-like." NIFTPs were the most molecularly diverse histologic type, with cases classified as "BRAF-like," "THADA-like," and "RAS-family-like." In conclusion, tumors fitting criteria for NIFTP are molecularly diverse, making it difficult to diagnose them with molecular studies, likely including matrial from cytopathology samples.

Entities:  

Keywords:  BRAF-like; Follicular variant papillary thyroid carcinoma; Non-invasive follicular thyroid neoplasm with papillary-like nuclear features; RAS-like; Thyroid cancer

Mesh:

Substances:

Year:  2019        PMID: 30645670     DOI: 10.1007/s00428-018-02512-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  5 in total

Review 1.  Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): Diagnostic updates and molecular advances.

Authors:  Ying-Hsia Chu; Peter M Sadow
Journal:  Semin Diagn Pathol       Date:  2020-06-10       Impact factor: 3.464

Review 2.  Noninvasive follicular neoplasm with papillary-like nuclear features (NIFTP): a new entity.

Authors:  Elisabetta Macerola; Agnese Proietti; Fulvio Basolo
Journal:  Gland Surg       Date:  2020-01

3.  Papillary Thyroid Carcinoma Variants are Characterized by Co-dysregulation of Immune and Cancer Associated Genes.

Authors:  Jaideep Chakladar; Wei Tse Li; Michael Bouvet; Eric Y Chang; Jessica Wang-Rodriguez; Weg M Ongkeko
Journal:  Cancers (Basel)       Date:  2019-08-15       Impact factor: 6.639

Review 4.  Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile.

Authors:  Ivana Kholová; Elina Haaga; Jaroslav Ludvik; David Kalfert; Marie Ludvikova
Journal:  Diagnostics (Basel)       Date:  2022-01-20

5.  Revised criteria for diagnosis of NIFTP reveals a better correlation with tumor biological behavior.

Authors:  Ana Carolina de Jesus Paniza; Thais Biude Mendes; Matheus Duarte Borges Viana; Débora Mota Dias Thomaz; Paula B O Chiappini; Gabriel A Colozza-Gama; Susan Chow Lindsey; Marcos Brasilino de Carvalho; Venâncio Avancini Ferreira Alves; Otavio Curioni; André Uchimura Bastos; Janete Maria Cerutti
Journal:  Endocr Connect       Date:  2019-11       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.